Clin Psychopharmacol Neurosci.  2019 Mar;17(2):211-221. 10.9758/cpn.2019.17.2.211.

Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels

Affiliations
  • 1Department of Psychiatry, Faculty of Medicine, Izmir Katip Çelebi University, Izmir, Turkey. oralelif@yahoo.com
  • 2Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
  • 3Department of Biochemistry, Faculty of Pharmacy, Ataturk University, Erzurum, Turkey.
  • 4Department of Psychiatry, Erzurum Regional Education and Research Hospital, Erzurum, Turkey.

Abstract

OBJECTIVE: This study investigated changes in urotensin-II (U-II) and endocan levels which can be used as an early biological marker of endothelial injury in the episode and remission phases of bipolar affective disorder (BAD).
METHODS
We compared endocan and U-II levels, which has been shown to be closely associated with neurotransmitter systems in addition to continuity of endothelial structure and inflammatory response, in patients with BAD in remission for at least one year (n=42) and in patients still in manic or depressive episodes (n=16) with healthy controls (n=30).
RESULTS
Both endocan and U-II levels were significantly higher in the bipolar patients than in the controls. Endocan and U-II levels were also significantly correlated with one another (p=0.000, r=0.833). Both endocan (p=0.000) and U-II levels (p=0.000) were significantly higher in the bipolar attack group compared to the subjects in remission, and in the remission group compared to the controls.
CONCLUSION
In this study we determined significantly higher endocan and U-II levels in BAD compared to the controls, while serum endocan and U-II levels of patients undergoing attacks were also significantly higher than those of the controls and also those of patients in remission.

Keyword

Endocan; Urotensins; Bipolar disorder; Endothelial injury
Full Text Links
  • CPN
Share
  • Twitter
  • Facebook
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr